Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pociredir Open-Label Extension in Sickle Cell Disease
NCT07401823Phase 2Terminated
- Sponsor
- Fulcrum Therapeutics
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pociredir in sickle cell disease (SCD), sponsored by Fulcrum Therapeutics. Started Mar 2026; status: terminated.
02
Drugs
pociredir
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07401823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401823.